24.11.2016 • NewsElaine BurridgeAllergantherapeutics

Allergan Buys US Chase Pharmaceuticals

(c) Westend61/Getty Images
(c) Westend61/Getty Images

Irish drugmaker Allergan has beefed up its pipeline for neurodegenerative disorders with the acquisition of US-based Chase Pharmaceuticals. Under the terms of the deal, Allergan has paid Chase an upfront fee of $125 million, but this could rise to $1 billion if all potential regulatory and sales milestone payment targets are reached.

Chase's lead compound, CPC-­201, which combines the most commonly prescribed acetylcholinesterase inhibitor (AChEI), donepezil, and the peripherally acting cholinergic blocker, solifenacin, is being investigated as a potential treatment for patients suffering from Alzheimer's. AChEIs have been shown to improve cognition in Alzheimer’s patients but those that are currently approved are only modestly effective because of dose-limiting side effects that include diarrhea, nausea and vomiting.

The biopharma’s next-generation formulation of donezepil is said to offer the possibility of greater and more tolerable dosing, and may provide the potential for significantly improved cognition and function in patients. David Nicholson, Allergan’s chief research & development officer, said the acquisition adds a new Phase 3 ready program for Alzheimer’s disease to its central nervous system (CNS) portfolio and builds on its commitment to develop innovative approaches to help patients suffering from the devastating illness. Allergan intends to take CPC-201 into a single Phase 3 registration study in 2017.

The Dublin-based firm has made several acquisitions since its failed merger with Pfizer earlier this year. Recent purchases include AstraZeneca’s Crohn’s disease drug MEDI2070, and US biotech firms Tobira Therapeutics, Retrosense Therapeutics and Akarna Therapeutics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.